Find Blarcamesine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 195615-83-9, Avex-73, Thd-dp-fm, Ae-37, Ae37, Blarcamesine [usan]
Molecular Formula
C19H23NO
Molecular Weight
281.4  g/mol
InChI Key
BOTHKNZTGGXFEQ-UHFFFAOYSA-N
FDA UNII
9T210MMZ3F

Blarcamesine
1 2D Structure

Blarcamesine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine
2.1.2 InChI
InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3
2.1.3 InChI Key
BOTHKNZTGGXFEQ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN(C)CC1CCOC1(C2=CC=CC=C2)C3=CC=CC=C3
2.2 Other Identifiers
2.2.1 UNII
9T210MMZ3F
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Anavex2-73

2. Tetrahydro-n, N-dimethyl-2,2-diphenyl-3-furanmethanamine Hydrochloride

2.3.2 Depositor-Supplied Synonyms

1. 195615-83-9

2. Avex-73

3. Thd-dp-fm

4. Ae-37

5. Ae37

6. Blarcamesine [usan]

7. Anavex-2-73

8. 9t210mmz3f

9. Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanemethanamine

10. 1-(2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine

11. Blarcamesine (usan)

12. Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine

13. 3-furanmethanamine, Tetrahydro-n,n-dimethyl-2,2-diphenyl-

14. 1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n-dimethylmethanamine

15. (r)-1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n-dimethylmethanamine

16. Unii-9t210mmz3f

17. Anavex

18. Ae 37

19. Blarcamesine [inn]

20. An2/avex-73

21. Avex-73?

22. Schembl181634

23. Chembl4297224

24. Gtpl11586

25. Dtxsid60941344

26. Bcp23552

27. Ex-a3143

28. Bdbm50559171

29. Anavex-2-73 Free Base (blarcamesine)

30. Db05592

31. Sb17187

32. Ncgc00387227-01

33. Ac-35490

34. Hy-105296

35. Cs-0025655

36. D11383

37. D87137

38. Q25110485

39. Rac-1-((3r)-2,2-diphenyloxolan-3-yl)-n,n-dimethylmethanamine

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 281.4 g/mol
Molecular Formula C19H23NO
XLogP33.5
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count2
Rotatable Bond Count4
Exact Mass281.177964357 g/mol
Monoisotopic Mass281.177964357 g/mol
Topological Polar Surface Area12.5 Ų
Heavy Atom Count21
Formal Charge0
Complexity298
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in breast cancer.


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty